Navigation Links
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
Date:6/22/2009

- FDA Agreement Reached on Phase 3 Study Design, Primary Endpoint and Histological Methodology -

CRANBURY, N.J., June 22 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the U.S. Food and Drug Administration (FDA) on the key protocol design elements of the pivotal trial, including the use of the surrogate primary endpoint of the change in the amount of kidney interstitial capillary GL-3, the substrate that accumulates in the cells of Fabry patients. In addition, the FDA is in agreement that the Company is eligible to seek Accelerated Approval for Amigal according to Subpart H regulations. The Company has begun submitting the Phase 3 protocol to investigational sites worldwide and expects to begin the dosing of subjects in the second half of this year.

John F. Crowley, President and CEO of Amicus stated, "The start of our Phase 3 trial with Amigal is a major milestone for Amicus and highlights our transition into a late-stage development company." Crowley continued, "We are very pleased with the outcome of our interactions with FDA around the design of this pivotal study and are confident we have set the stage for a successful Phase 3 study. We continue to believe that Amigal may be an important treatment option for patients who suffer with Fabry disease and a significant step forward for them and their families."

Raphael Schiffmann, MD, Director of the Institute of Metabolic Disease, Baylor Health Care System Foundation, commented, "Having been involved in Fabry research for more than 15 years and considering the Phase 2 data with migalastat, I am pleased that the Phase 3 trial is st
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015 Konica Minolta ... announced today a new, integrated portable X-ray ... solution is now available with a larger integrated console, ... mounted system offers a larger viewing area to simplify ... provides additional space for accessories and storage, along with ...
(Date:3/3/2015)... 3, 2015  Columbia Laboratories, Inc. (Nasdaq: ... Company"), a specialty pharmaceutical company focused on pharmaceuticals for ... the 27th Annual ROTH Conference, which will take place ... Dana Point, California . Management,s presentation ... a.m. Pacific Time (12:00 p.m. Eastern Time) in the ...
(Date:3/3/2015)... 2015  Web Industries, Inc., a leading provider ... Medical Device, Advanced Composites, Consumer Products, and Wire ... Medical Specialties Preferred Converter by 3M,s Medical Specialties ... to streamline their supply chains by using Web ... materials, intermediate converting services, and contract manufacturing and ...
Breaking Medicine Technology:Konica Minolta Medical Imaging and Shimadzu Medical Systems USA Introduce MobileArt Evolution EFX AeroDR-i with 17" Touch Monitor to Simplify Operation 2Konica Minolta Medical Imaging and Shimadzu Medical Systems USA Introduce MobileArt Evolution EFX AeroDR-i with 17" Touch Monitor to Simplify Operation 3Web Industries Receives 3M Preferred Converter Status 2
... advanced leukemia and myelodysplastic, syndrome patients presented ... N.J., Dec. 10 Celator Pharmaceuticals today,announced results ... a liposomal,formulation that incorporates a synergistic ratio of ... and myelodysplastic,syndromes. While dose escalation in the study ...
... Dec. 10 The US Food and,Drug Administration ... small,open, long-term, clinical studies in patients with gastro-esophageal ... study) or NEXIUM(R) (LOTUS study) treatment., AstraZeneca ... conclusion which states,"FDA continues to conclude that long-term ...
Cached Medicine Technology:Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients 2FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium) 2FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium) 3FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium) 4
(Date:3/3/2015)... Daylight Savings Time may lead to your kids ... for parents. , Parents and their children may feel a ... they set their clocks forward one hour for Daylight Savings ... one hour earlier -- you will have already lost one ... about “sleep hygiene” for their kids and teens this week, ...
(Date:3/3/2015)... 03, 2015 Topical BioMedics, Inc., announces its ... streamed live on Tuesday, March 10th, 12pm – 1pm and ... and accessible 24/7. , The Pain Management ... for the March 10th workshop is “Opioid Addiction: An ... the U.S. represents 5% of the world’s population, yet consumers ...
(Date:3/3/2015)... MD (PRWEB) March 03, 2015 Today ... Association (ASHA) is using the occasion to applaud and ... campaign by the World Health Organization (WHO) for stemming ... campaign aims to encourage young people to practice safe ... audio technology, attending concerts or sporting events, or engaging ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 The ... better predict antidepressant treatment outcomes for patients with ... than any of the individual genes that comprise ... investigators from the Mayo Clinic and Assurex Health, ... , The proprietary technology of the GeneSight ...
(Date:3/3/2015)... With a grant of more than $4.5 ... has been named a national coordinating center by the ... for Health: Improving Community Health Through Innovations in Financing ... health and reduce disparities through innovations in collaboration and ... of the center and up to 10 communities over ...
Breaking Medicine News(10 mins):Health News:Don’t Let Daylight Savings Disrupt Your Child’s Sleep 2Health News:Topical BioMedics Hosts March Pain Management Webinar 2Health News:Topical BioMedics Hosts March Pain Management Webinar 3Health News:Topical BioMedics Hosts March Pain Management Webinar 4Health News:Topical BioMedics Hosts March Pain Management Webinar 5Health News:ASHA Applauds Launch of New WHO Campaign 2Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 2Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 3Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 4Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 5Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 6Health News:Robert Wood Johnson Foundation Names Georgia Health Policy Center National Center for Bridging for Health Initiative 2
... have now proved using a specialized mouse model that ... neurons.// The results of this study have for the ... ,Also known as apoE, this cholesterol-carrying protein ... the major known genetic risk factor for Alzheimer's disease, ...
... published in the journal Carcinogenesis show that exercise can offer ... that had a round the clock access to wheels took ... that exercise and a restricted diet had a healthy effect ... ,The first study exposed mice to ultraviolet B ...
... Dental Health Foundation has found that more than 60 percent ... clean off food debris// struck in between their teeth. Items ... use, the survey said. ,More disturbingly, the survey ... teeth giving rise to oral health problems and bad breath. ...
... the form of health claims that green tea is no ... a model qualified health// claim says "Daily consumption of at ... a source of catechins may reduce a number of risk ... evidence is supportive, but not conclusive, for this claim. (Green ...
... (AIIMS) here is running short of faculty members and its ... informed Friday. ,Replying to a question, minister of state ... AIIMS was running with just 479 faculty members as against ... the house that during 2003-05, 20 faculty members had either ...
... rate in Madhya Pradesh, Bhopal Archbishop Pascal Topno has ... ,With 13,000 reported deaths every year during or ... is one of the highest in the country. ... Niketan Welfare Centre here, Topno urged them to tap ...
Cached Medicine News:Health News:Alzheimer's-linked apolipoprotein E produced by neurons, Gladstone study 2Health News:Green tea’s health claims questioned: FD 2Health News:Green tea’s health claims questioned: FD 3
Cushing bayonet....
Straight, blunt tips....
Angled, pointed, with attached cable for Valleylab and other brands generators....
Autoclavable reusable pencil for Aaron 800 & 1200 - comes with generator or 1/box....
Medicine Products: